primarily due to: • Revenue from sales and cost of goods sold The total sales volumes reduced from last year quarter by 4% and average HRC selling price reduced from last year quarter by 17% mainly due to the
- Despite the impact of COVID-19 pandemic, OSP managed to deliver Q1’20 Net profit* at THB 926 million (+4.2% YoY, +12.5% QoQ), with Q1’20 net profit* margin of 13.8% (-20 bps YoY, +140 bps QoQ), from the
Company Limited (“the Company”) had revenue from services of THB 1,151.6 million, decreased by 34.3% from the six months ended of the year 2019, as a result of the temporary suspension of hotel operation in
million Baht in 2020, and net loss of 156.50 million Baht in 2019. The Company’s net profit has increased by 645.01 million Baht or 412.16 % from the previous year. In 2020, the Company realized the after
Company’s net profit has decreased by 64.90 million Baht or 13.29 % from the previous year. In 2021, the Company realized the after adjusted EBITDA of 540.81 million Baht, and the year 2020 of 609.04 million
Thailand in 2023 growing only 1.9%, decelerating from 2.5% in the previous year, from a slowdown in public investment and public consumption due to the delay of government’s budget allocation, although the
-owned of the Listed Subsidiary 2. The Construction of Wattanapat Samui Hospital Building Contractor: Waiting 3. Buying the Medical Instruments The Company will appropriately make a purchase from
www.interpharma.co.th Inter Pharma Co. Ltd. 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th a surge in revenues from sales of
period ended on March 31, 2016, as follows: Particulars Q1/2016 Q1/2015 Increase (Decrease) Million Baht Million Baht Million Baht % Revenue Revenue from selling immovable property 222.23 111.55 110.69